Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

MUNASET · Multiparametric nanoelectronic biosensors for therapy response testing

HORIZONStatus: SIGNED1 October 202330 September 2027EU funding €4,000,206Call HORIZON-CL4-2022-DIGITAL-EMERGING-02

Proteases recently emerged as a promising new class of biomarkers with a broad diagnostic, prognostic and therapeutic potential for different human diseases including neurological and psychiatric diseases, several types of cancer, and immune system disorders. However, there is a lack of tools for real-time activity analysis of disease-related protease biomarkers. To address this issue, we propose to develop a highly sensitive graphene-based biosensor platform for parallel detection of multiple proteases in serum. We will exploit a new label-free sensing mechanism based on charge removal due to cleavage of designer peptides by proteases. As a specific business case, we plan to address therapy response prediction along treatment of major depressive disorder (MDD). MDD is one of the most common and burdensome mental disorders worldwide. MDD is also among the most expensive brain diseases in Europe. While effective treatments exist, there is a high variability in treatment response. There are no serum-based tests to predict personalized therapy for MDD patients. The effective treatment is identified through trial and error, a great burden for patients and the health care system. A rapid, sensitive and easy-to-use test would allow faster and more precise treatment identification, improving therapy outcomes and reducing hospitalization times. Here, we plan to detect two protease biomarkers associated with MDD. The biosensors will be validated in clinical serum samples. Arrays of graphene biosensors will be integrated on silicon wafers with a multiplexed readout matrix to realize a miniaturized sensor system with multi-analyte detection capability, high dynamic range, high precision, low detection limit, and low material consumption. The resulting platform technology may enable various point-of-care diagnostic and therapy prediction tools. This will help secure industrial leadership of the EU over the entire value chain of novel graphene-based bio-analytical tools.

Consortium · 6 organisations

coordinator

HOCHSCHULE KAISERSLAUTERN

DE · €1,357,008

participant

TEKNOLOGIAN TUTKIMUSKESKUS VTT OY

FI · €1,000,760

participant

PRO-ACTIVE

BE · €431,500

participant

GRAPHENEA SEMICONDUCTOR SL

ES · €615,000

participant

UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ

DE · €292,846

participant

JOHANNES GUTENBERG-UNIVERSITAT MAINZ

DE · €303,093

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.